ResMed Inc. RMD

NYSE · Healthcare · Medical - Instruments & Supplies

$235.63

Close on Fri, 20 Nov 2026 · market value $33.1B

What the price is betting on

Below its record

At $236, the price assumes revenue grows about 4.1% a year for five years, from $5.7B to about $7B by FY2031. That is about the same as what analysts expect for the next two years and less than the company's own last three years.

The price assumes4.1%
Analysts, next two years4.8%
Last 3 years9.9%

Revenue growth a year. The price figure comes from a reverse DCF at a 8.2% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than RMD? Check up to 5 of your stocks at once, free, no account.

0$2B$4B$6B$8B$5.7B'23'24'25'26Sep '26'27'28'29'30'31What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$224

Base

$252

Bull

$284

Today $236

  • Bear $224. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $252. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $284. Cash flow grows 8% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2027$5.9B$5.8B, on the path
  3. FY2028$6.2B$6.2B, on the path
  4. FY2029$6.4B$6.6B, on the path
  5. FY2030$6.7B$7.1B, on the path
  6. FY2031$7BThe full bet

Each year's revenue at 4.1% growth from $5.7B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Instruments & Supplies · listed on NYSE

Revenue, FY2026
$5.7B
Growth, 3 years a year
9.9%
Cash margin
29%
Net cash
$643M
Shares, 3-year change
−1%
Dividend yield
1.1%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.